Dramatic relapse of seizures after everolimus withdrawal

Curatolo, 2015, Mechanistic target of rapamycin (mTOR) in tuberous sclerosis complex-associated epilepsy, Pediatr Neurol, 52, 281, 10.1016/j.pediatrneurol.2014.10.028 Vignoli, 2013, Epilepsy in TSC: certain etiology does not mean certain prognosis, Epilepsia, 54, 2134, 10.1111/epi.12430 Franz, 2015, Everolimus for subependymal giant cell astrocytoma: 5-year final analysis, Ann Neurol, 78, 929, 10.1002/ana.24523 Krueger, 2013, Everolimus treatment of refractory epilepsy in tuberous sclerosis complex, Ann Neurol, 74, 679, 10.1002/ana.23960 Perek-Polnik, 2012, Effective everolimus treatment of inoperable, life-threatening subependymal giant cell astrocytoma and intractable epilepsy in a patient with tuberous sclerosis complex, Eur J Paediatr Neurol, 16, 83, 10.1016/j.ejpn.2011.09.006 Cardamone, 2014, Mammalian target of rapamycin inhibitors for intractable epilepsy and subependymal giant cell astrocytomas in tuberous sclerosis complex, J Pediatr, 164, 1195, 10.1016/j.jpeds.2013.12.053 French, 2016, Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study, Lancet, 388, 2153, 10.1016/S0140-6736(16)31419-2